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INTRODUCTION 
Immunoglobulin E (IgE) is a major contributing factor in mul-
tiple airway diseases, including allergic rhinitis (AR) and chronic 
rhinosinusitis with nasal polyposis (CRSwNP). However, mea-
suring IgE by classical systemic tests fails to give an adequate 
idea of local IgE in the target organ, the nose.1-4 In this review, we 
summarize the evidence of local production of IgE in sinonasal 
diseases, and clinical implications will be discussed. 
Diagnostic tools in rhinitis may not be sufficient to differenti-
ate between allergic, non-allergic, and local allergic rhinitis 
(LAR), as local IgE normally is not measured. 
In chronic rhinosinusitis, different disease subgroups exist5 
with their inherent pathomechanisms, and it is challenging to 
find good markers to further categorize the nasal-polyposis 
population. It would be especially interesting to determine the 
endotype in which IgE, whether or not systemic, is crucial in 
the pathogenesis. The response to targeted therapy as anti-IgE 
can be predicted. 
Classical pathway for development of IgE-positive B cells 
Mature naïve B cells encounter antigen processed and pre-
sented by dendritic cells in peripheral lymphoid organs. They 
become activated after interaction with T cells specific for an 
incoming antigen. After activation on the boundary between B-
cell follicles and T-cell zones, the B cells have 2 options. They 
migrate to the follicle, proliferate, and form germinal centers, or 
they migrate to an extra-follicular region, proliferate, and differ-
entiate into short-lived plasma cells. B cells in the germinal cen-
ter undergo antibody affinity maturation by means of somatic 
hypermutation (SHM), class switch recombination (CSR), clon-
al expansion, and selection. 
SHM and CSR are necessary to create enormous diversity 
found in the antibody and T-cell receptor repertoires required 
for an effective immune response. As mentioned before, these 
reactions generally take place within germinal centers, which 
are typically located in secondary lymphoid tissues, such as 
tonsil tissue, lymph nodes, and the spleen. SHM is a modifica-
tion of the genome sequence in somatic cells by substitution of 
a single base in variable regions of Immunoglobulin (Ig) genes 
in B cells. CSR in the Ig heavy chain gene locus of the constant 
region is necessary to class switch from IgM, IgG, or IgA to IgE, 
resulting in B cells expressing IgE. Both SHM and CSR are initi-
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ated by activation-induced cytidine deaminase (AID),6 and 
thus this molecule can be used as a marker for these processes. 
When a mature B cell alters its receptor in response to antigenic 
stimulation, this is called receptor revision (RR), initiated by re-
combination-activating gene products (RAG1 and RAG2). 
Signals from T helper cells are mandatory for CSR to IgE+ 
cells, namely interleukin (IL) 4 and IL13, and the ligation be-
tween CD40 on B cells and CD40ligand on T cells.7 After bind-
ing of the promotor Iε, the production of germline transcripts 
(εGLT) is intitiated. This precedes IgE class switching and re-
combination of the heavy chain by AID. The outcome is a ma-
ture ε chain mRNA and a circular fragment of DNA that is 
looped out, known as a ‘switch circle.’ Ergo switch circles can be 
used as a marker of ongoing CSR in B cells. 
Isotype-switched B cells that leave the germinal center reac-
tion become either memory B cells or long-lived plasma cells. 
Memory B cells divide, whereas long-lived plasma cells do not 
self-renew. Memory B cells secrete little Ig, but rapidly provide 
antigen-specific antibody-secreting plasma cells upon antigen 
recall. Long-lived plasma cells provide long-term maintenance 
of antigen-specific antibody titers. This is likely the case for IgE 
as well.8 Both B memory cells and long-lived plasma cells are 
the cellular source of IgE memory, and they ensure humoral 
memory. In a murine model, the results of the group of Erazo9 
suggest that IgE+ cells that exit the germinal center reaction 
preferentially develop into plasma cells. The differentiation of B 
cells into plasma cells is directed by B cell-activating factor of 
the TNF-family (BAFF) and B-lymphocyte-induced maturation 
protein (BLIMP).
AR and non-AR 
IgE in AR and non-AR 
Rhinitis is traditionally categorized as allergic, infectious, or 
non-infectious non-allergic rhinitis (NINAR). NINAR is diag-
nosed by exclusion,10 meaning that this category includes a het-
erogeneous group of rhinitis patients with a poorly defined 
pathogenesis. Mostly, no etiology is found, and this subgroup is 
known as idiopathic rhinitis. 
IgE is one of the most important markers of allergy, as it is the 
major contributing factor in most types of allergic disease.11 
Traditionally, the distinction between allergic and non-allergic 
rhinitis is based on skin prick tests and serum IgE analysis. 
However, in a subgroup of patients with a typical history sug-
gestive of allergy, these tests are negative, but measurement of 
local IgE can show elevated levels. This observation suggests 
that a local form of rhinitis may exist, known as ‘LAR’. 
AR and Systemic IgE 
Respiratory mucosa is a site of IgE induction during allergic 
airway inflammation. The group of Eckl-Dorna12 investigated 
the role of blood-derived plasma cells and B cells in the pro-
duction of allergen-specific IgE. In a series of cell separation ex-
periments performed by negative depletion and positive selec-
tion, they found that the majority of circulating specific IgE an-
tibodies is not derived from IgE-producing cells in the blood. 
This result suggests that the production at the target organ is 
the probable source.12 Serum IgE in AR might thus be a result of 
spill over rather than the reverse; nearly all of the serum IgE 
may be derived from mucosal sites. 
LAR 
Conventionally, an immune response is primed in germinal 
centers within lymph nodes, whereas the effector function of 
antibodies is peripheral, e.g. mucosal. In AR, however, all events 
may occur peripherally.13 Localized IgE-mediated inflamma-
tion may be suspected in a small subgroup of the idiopathic rhi-
nitis group with negative skin prick testing, where allergen-spe-
cific IgE is measurable in nasal secretions of patients.14 Also, 
studies have proven that the localized cellular pathogenesis is 
analogous to that in patients with AR, suggesting that these 
‘non-allergic’ subjects are in fact allergic. 
Evidence of Local IgE production 
In AR, IgE-positive B cells would reside in the nasal mucosa, 
as local IgE production has been perceived in vitro15 and in 
vivo.14,16,17 The possibility that IgE is produced locally in the tar-
get organ was first proposed after an experiment in children 
with AR to house dust mite and asthma. IgE was measured in 
the serum and in nasal secretions in steady state, and kinetic 
studies were added. It was seen that after re-exposure, local IgE 
increased more rapidly than serum IgE.18 In another experi-
ment, levels of specific IgE measured in nasal secretions exceed 
levels measured in serum of patients diagnosed with AR to ce-
dar pollen.19 Furthermore, in cases where no serum specific IgE 
is measurable, elevated levels are found in nasal secretions. 
This was demonstrated for HDM-specific IgE16,20 and for specif-
ic IgE to grass/olive pollens14 in non-allergic patients with posi-
tive nasal provocation tests. 
Kleinjan et al.17 provided evidence for local production of spe-
cific IgE, as IgE-positive mast cells, plasma cells, and B cells11 
are found in inferior turbinate tissue from patients with AR. The 
presence of long-lived plasma cells in the mucosa of subjects 
with AR was also suggested by Smurthwaite et al.21 who dem-
onstrated persistent IgE synthesis between seasons in explants 
of hay fever patients. Ex vivo stimulation of tissue obtained 
from allergic patients leads to an increase in IgE, meaning that 
all is available locally to produce IgE.13 Cameron et al.22 demon-
strated elevated levels of IL4 in AR, meaning the nasal mucosa 
in AR is a favorable environment for CSR. Hence, local produc-
tion and release of IL4 and IL13 by T cells and mast cells may 
regulate the local IgE production.23 These cells also carry the 
CD40 ligand necessary for DNA recombination and IgE synthe-
sis.23 Regarding functionality, Pawankar et al.15 demonstrated 
up-regulation of FcεRI on mast cells in response to locally pro-
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duced specific IgE. Subsequently to the increased IgE cross-
linking, more mast cells are activated and degranulate, promot-
ing allergic reactions. 
As previously discussed, evidence points at the local synthesis 
and secretion of IgE. Does CSR to IgE+ B cells and affinity mat-
uration occur in distant lymphoid tissues before migrating to 
the target organ or do they first migrate and only then class 
switch? 
In human nasal mucosa of allergic individuals, GC formation 
has not yet been demonstrated,24 although SH and CSR to IgE 
have been described.3,4,9,24,25 In an ex vivo experiment with nasal 
mucosa from grass pollen-sensitized subjects, class switching is 
found upon allergen stimulation.4 The group of Coker26 detect-
ed local bias to the VH5 germline gene family, while no VH5 
overexpression was detected in the blood. Furthermore, AID is 
continuously expressed, representing a fundamental aberra-
tion in the mucosa of AR patients.4,27 Next to AR, local IgE for-
mation is also present in CRSwNP. IgE in nasal polyps is poly-
clonal, whereas IgE in AR is monoclonal or oligoclonal. In con-
trast to AR, germinal center formation has been documented in 
nasal polyps,28 autoimmune diseases,27 and lower airways.13 
This information illustrates that the nasal mucosa has the in-
trinsic capability of affinity maturation by SHM, clonal expan-
sion, and CSR to IgE.3,24,27,29 
Pathomechanisms underlying AR 
To understand the role of IgE in allergic and ‘non-allergic’ rhi-
nitis, knowledge of pathomechanisms is essential. Allergic in-
flammation typically comprises an early and a late phase orga-
nized by structural epithelial cells, residential mast cells, and in-
filtrating eosinophils/basophils/T cells. Cytokines released from 
mast cells and T cells mediate local IgE production by B cells. 
1) The role of epithelial cells 
Epithelial cells are not merely functional as a barrier, but upon 
activation they can also release immunomodulatory substanc-
es that regulate Th2 cytokine response, including eicosanoids, 
endopeptidases, cytokines (thymic stromal lymphopoietin 
[TSLP], IL25, and IL33), and chemokines. Epithelial cells can be 
activated by an IgE-mediated mechanism. 
2) Immediate response 
The activation of mast cells is crucial in the immediate re-
sponse, and activation by antigen cross-linking of IgE is a well-
known mechanism. Sensitized mast cells have both high and 
low affinity receptors for IgE on their surface, the abg2 tetramer 
FcεRI and the ag2 trimer FcεRII, respectively. The latter is also 
termed CD23 receptor and found on a broad range of cells.30 
These receptors bind IgE, and upon cross-linking the mast cell 
degranulates and releases different mediators like histamine, 
tryptase, newly synthesized lipid mediators, cytokines, and 
chemokines. Histamine, leukotrienes, and prostaglandins 
cause clinical symptoms, such as sneezing, running nose, and 
nasal obstruction. 
Basophils are phenotypically similar to mast cells, as they are 
granulocytes containing histamine and expressing FcεRI. Thus, 
upon cross-linking with specific IgE, they release histamine. 
However, basophils can migrate to lymphoid tissues, while mast 
cells cannot. It is suggested that effector functions of basophils 
are heterogeneous according to the eliciting factor. IL3-elicited 
basophils would be highly responsive to IgE, conversely to 
TSLP-elicited basophils that would be non-responsive to IgE.31 
3) Late phase response 
The release of cytokines and chemokines by mast cells in the 
immediate phase response, which starts within minutes and 
lasts for 2-3 hours, is important for the subsequent late phase 
response. The late phase response starts 4-6 hours after stimu-
lation and lasts for 18-24 hours. An infiltrate containing T help-
er 2 (Th2) cells, eosinophils, and basophils is characteristic of 
this phase. Th2 cells are important for the production of key cy-
tokines, including IL4, IL5, IL9, and IL13. These cytokines are 
essential for antibody class switching, regulation of local and 
systemic IgE synthesis, recruitment of eosinophils, basophils, 
and mast cells, and survival of eosinophils. It is mostly assumed 
that eosinophils differentiate within the bone marrow in re-
sponse to eosinophilopoietins. In AR, however, a subset of eo-
sinophils would differentiate within the nasal mucosa in a high-
ly IL5-dependent manner.32 Langerhans cells are dendritic cells 
of the skin and mucosa. They are professional antigen-present-
ing cells (APCs), which process aeroallergens deposited on the 
mucosa and subsequently present the antigens to T cells. Th2 
cells release their mediators upon recognition of antigen pre-
sented by APCs. The Th2 cytokines IL4, IL13, and CD40L in-
duce selective somatic recombination of Ig heavy chain regions 
in B cells before maturation into IgE-producing plasma cells. 
Pathomechanisms underlying non-AR 
In ‘non-allergic’ rhinitis, no systemic markers of allergy can be 
detected. These patients could however still be allergic in the 
case of LAR, although most cases are truly non-allergic. Here, a 
broad differential diagnosis has to be made. Endonasal infec-
tions are a common cause of non-allergic rhinitis, and com-
plaints can persist long after resolution of the infection. Non-
specific exogenous irritants, such as tobacco smoke, pollution, 
dust, smog, perfumes, solvents, and occupational irritants, 
could also trigger mucosal inflammation. Furthermore, rhinitis 
can be elicited by foods and beverages, namely ‘gustatory rhini-
tis’ by certain oral medications, or by overuse of decongestant 
nasal sprays, called ‘rhinitis medicamentosa.’ Changes in hor-
mones due to pregnancy or hypothyroidism, for example, 
could result in rhinitis. In the elderly, watery rhinitis or geriatric 
rhinitis is often seen. Non-IgE-mediated hypersensitivity can 
also explain the discrepancy between IgE testing results and 
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clinical findings, for example, T-cell mediated delayed type hy-
persensitivity and activation of mast cells by Ig free light chains 
(FLCs).33,34 
Evidence increases for the possibility that a T cell-mediated 
inflammatory reaction to common antigens sustains asthma 
and AR, especially when atopic dermatitis is identified in the 
history.34 Here again, negative skin prick test (SPT) and RAST 
can be expected. 
Ig FLC could serve as an alternative for IgE in eliciting inflam-
mation in allergic disorders, including food allergy, atopic der-
matitis, rhinitis, and asthma.35 FLCs can cause immediate hy-
persensitivity through mast cell activation, and they are found 
in both atopic and non-atopic rhinitis.35 Moreover, Powe et al.33 
demonstrated a link between FLC immunoglobulins and mast 
cells in the nasal mucosa, which suggests an association be-
tween Ig FLC and mast cell-mediated nasal hyperreactivity. 
The role of FLC in AR is not clear, and further studies are neces-
sary to investigate the function of FLC in local hypersensitivity. 
Clinical implication: diagnostic workup of AR and non-AR 
Currently, the diagnostic workup of AR must consist of a his-
tory of the patient, with most important differentiation between 
intermittent and persistent symptoms and between mild and 
moderate to severe AR following the ARIA guidelines. In addi-
tion, clinical examination along with anterior rhinoscopy and 
nasoendoscopy is required. At last, allergen extract-based IgE 
tests are indispensable, such as SPT and the measurement of 
specific IgE antibodies in serum. Though these conventional 
tests are expected to be negative in cases where IgE is only situ-
ated in the nasal mucosa and those where rhinitis is induced by 
non-IgE-mediated mechanisms. These patients are classified 
as ‘non-allergic,’ although additional testing for local IgE may 
reveal a local allergic response in a subgroup of patients. In 
these cases where history is truly suggestive of AR and currently 
used tests are negative, it has to be questioned whether mea-
surement of systemic IgE levels is sufficient for the diagnostic 
workup. 
Additional testing by means of nasal provocation, as proposed 
by Rondón et al.36 or measurement of local IgE in the nasal mu-
cosa can be considered to reveal LAR. However, it is currently 
unclear how large this subgroup is; findings from our clinic/
group point to rather small numbers.37 Methods to measure lo-
cal mediators have not yet been standardized, and this will be 
discussed further in this review. To determine whether T cell-
mediated, delayed hypersensitivity lies at the basis of the com-
plaints, an Atopy Patch Test can be useful34; however, the rele-
vance of this test in AR has not yet been established. 
Clinical implication: treatment of AR and non-AR 
The correct diagnosis and knowledge of pathophysiology are 
essential in establishing the best treatment for a patient. 
Mast cells are crucial in allergic inflammation, and different 
treatment options aim to block their effect. Traditionally, topi-
cal corticosteroids and antihistamines are prescribed. 
Avoidance of allergens if possible is an important step, for in-
stance, in AR to mold or cat allergens. In most cases, however, it 
seems that this is hardly effective or impossible, such as in the 
case of AR to grass pollen or house dust mite. Only when it is 
known to which allergen the patient is sensitized, avoidance of 
allergen is possible, and/or immunotherapy can be considered. 
Recent diagnostic tests based on recombinant allergens, epit-
opes, and peptides allow more precise diagnosis of allergy. New 
immunotherapy strategies that would be more effective and 
safer than conventional allergy vaccines aim to suppress IgE-
mediated inflammation. T-cell tolerance can be induced by ad-
ministration of peptides containing T-cell epitopes, carrier-
bound allergen peptides, or recombinant hypoallergens. 
Targeted treatments using antibodies are developing. In aller-
gic diseases, such as AR, asthma, food allergy, and allergic der-
matitis, anti-IgE or omalizumab has been investigated. This hu-
manized monoclonal antibody targets the Cε3 domain of IgE, 
reducing free IgE by forming a biological inert molecule. Fur-
thermore, omalizumab down-regulates FcεRI on effector cells, 
and it would also decrease IgE synthesis by inducing an anergic 
state in IgE+ B cells.38 Omalizumab has a good clinical effect in 
allergic diseases39 that lasts for about 4 months, and it has a low 
incidence of side effects.40 This treatment is, in theory, an option 
in AR. However, the high cost-effectiveness ratios41 result in re-
striction of indications. Theoretically, rituximab or anti-CD20 
could also be an option to inhibit IgE-producing cells. 
To conclude, allergen avoidance (if possible), local corticoids, 
antihistaminic drugs, and leukotriene receptor antagonists are 
the first-line treatment options. Immunotherapy can be consid-
ered in certain cases where the conventional treatment is not 
sufficiently effective. In this way, a good control of symptoms is 
achievable and omalizumab or rituximab are not indicated for 
AR as such. 
CRSwNP 
Definition 
The term chronic sinusitis covers a wide range of sinus diseas-
es, in which the mucosa is inflamed with symptoms on most 
days lasting at least 12 weeks without complete resolution. In 
the pathophysiology, intrinsic (for example genetic) and extrin-
sic (for example microbial, environmental, and iatrogenic) fac-
tors may be involved, which can act locally or systemically. 
Two phenotypes are currently distinguished, namely chronic 
rhinosinusitis without nasal polyposis (CRSsNP) and CRSwNP. 
However, some authors believe that different disease entities 
classified as chronic sinusitis are a continuum of the same dis-
ease. These phenotypes show considerable overlap in symp-
toms, but can be differentiated from each other with reason-
able certainty by endoscopy. 
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The definition ‘chronic sinusitis’ suggests a single clinical enti-
ty, but in reality it represents multiple overlapping entities with 
different inflammation patterns. 
In CRSsNP, mostly Th1-skewed neutrophilic inflammation is 
found with elevated levels of interferon-γ (IFNγ) and transform-
ing growth factor-β (TGFβ), whereas inflammation in CRSwNP 
is often Th2-skewed eosinophilic inflammation with elevated 
levels of IL5 and IgE.5 However, patients with CRSwNP also 
form a heterogeneous group with different endotypes, meaning 
that inflammation patterns and T helper subsets vary. 
In the Western countries, the majority of nasal polyps is char-
acterized by Th2-skewed inflammation, dominated by cyto-
kines that promote production of IgE and eosinophilic inflam-
mation. IL4 stimulates proliferation and differentiation in Th2 
cells and mediates CSR to IgE by stimulating the synthesis of 
ε-germline gene transcript (GLT). IL5 is elevated in CRSwNP 
and remarkably increased in CRSwNP accompanied by non-al-
lergic asthma and aspirin sensitivity.42 IL5 mediates eosinophil 
survival, differentiation, and recruitment to the nasal mucosa, 
and causes secretion of eosinophil cationic protein (ECP).43 
ECP is an indicator of eosinophilic activation, and local ECP 
correlates with local IgE.44 The local inflammatory pattern 
could be related to the type of bacterial colonization. Coloniza-
tion with Gram-positive bacteria, for example, Staphylococcus 
aureus (SA) is common in individuals with nasal polyps char-
acterized by elevated IL5, ECP, and total IgE. In Asian popula-
tions, the inflammation in CRSwNP is frequently predominant-
ly neutrophilic.45 This pattern is associated with greater Gram-
negative bacterial colonization. Patients with nasal polyps and 
cystic fibrosis have Th1/Th17-skewed neutrophilic inflamma-
tion with highly increased expression of IL17 and IFNγ.5 
Biochemical markers that could be used to differentiate be-
tween CRSsNP and CRSwNP in Caucasians are ECP, IL5, and 
IgE. Markers to differentiate between CRSwNP and cystic fibro-




Total IgE is often highly increased in nasal polyp mucosa, and 
IgE specific to staphylococcal enterotoxins can be present inde-
pendently of serum total/specific IgE.46 The presence of plasma 
cells in the mucosa insinuates local production of IgE, which is 
polyclonal and functional.47 
In atopic nasal polyp patients, local IgE production can be the 
effect of stimulation with allergens.48 However, local hyperim-
munoglobulinemia is also present in non-atopic patients, 
meaning that elevated IgE levels result from other pathways as 
well. The cytokines IL25 and IL33 can induce IgE-mediated in-
flammation by stimulating a non-T cell source to produce IL4, 
Fig. 1. Pathways resulting in local IgE production in CRSwNP. In the first part, dendritic cells of the skin and mucosa process aeroallergens deposited on the mucosa, 
and subsequently they present antigens to T cells. T helper 2 cells release their mediators upon recognition of antigens presented by antigen-presenting cells. The Th2 
cytokines IL4, IL13, and CD40L induce selective somatic recombination of immunoglobulin heavy chain regions in B cells before maturation into IgE-producing plasma 
cells. IL5 stimulates eosinophil growth and differentiation. Alternatively, IgE is produced by stimulating innate lymphoid cells to release IL4, IL5, and IL13. 
De Schryver et al.
Allergy Asthma Immunol Res. 2015 July;7(4):321-331. http://dx.doi.org/10.4168/aair.2015.7.4.321
Volume 7, Number 4, July 2015
326 http://e-aair.org
IL5, and IL13, namely innate lymphoid cells (ILC)49 (Fig. 1). A 
role of mast cells in enhancing eosinophilic inflammation in 
chronic rhinosinusitis is suggested. Ex vivo experiments dem-
onstrate that activation of IgE cross-linking in CRSwNP47 and 
FLCs present in nasal polyps could mediate local immune re-
sponses.50 FLC concentrations correlate with IL5, IL6, and local 
IgE. Furthermore, a decrease in local FLCs is seen after treat-
ment with anti-IL5, presuming that IL5 creates an environment 
that favors FLC production.50 Next to IgE and FLC, locally pro-
duced IgA51 could also be involved in the activation of mast 
cells and eosinophils. The role of IgA is not clear, but elevated 
levels of IgA are often found in patients with chronic mucosal 
inflammation. In CRSwNP as well, elevated levels of IgA is 
found in tissue homogenates,51 although this could be ex-
plained by a decreased translocation of IgA from the epitheli-
um of the lamina propria into nasal secretions.52  
Germinal center reaction in nasal polyposis 
As mentioned earlier, it is generally believed that GC are situ-
ated in lymphoid tissues, meaning that affinity maturation by 
SHM and CSR takes place in these lymphoid tissues. 
The involvement of local IgE production has been investigat-
ed by comparing key markers of Th2 inflammation and GC re-
actions in nasal polyp tissue versus control tissue. We measured 
elevated levels of IL4, ε-GLT, ε-mRNA, and local IgE, which all 
point at local CSR. 
Enhanced differentiation of B cells into plasma cells in nasal 
polyps can be concluded from the increased number of plasma 
cells and ratio of plasma cells to B cells, together with the ele-
vated BAFF levels. The up-regulation of RAG1/RAG2 points at 
local RR. The presence of switch circle transcripts points at on-
going local CSR. To conclude, our group was the first to reveal 
formation on GC-like structures in polyps with local RR, class 
switching to IgE, and B-cell differentiation into IgE-secreting 
plasma cells.1 Because T follicular helper (Tfh) cells and IL21 
produced by these cells are important in regulating B cells in 
GC and lymphoid accumulations are found in nasal polyps, a 
new study was conducted. Here, IL21 and IL21- positive T help-
er cells were measured in nasal tissues of CRSwNP, CRSsNP, 
and controls. Elevated levels of IL21 and IL21-positive T helper 
cells were found in CRSwNP, and after stimulation with staphy-
lococcal enterotoxin (SE) B during 24 hours a significant in-
crease of IL21 in the CRSwNP was seen. In the same study, high 
expression of B lymphocyte-induced maturation protein-1 
(Blimp-1) and B-cell lymphoma-6 (Bcl-6) was found. These 
molecules are antagonists with Bcl-6 being the regulator of Tfh 
cell differentiation and Blimp-1 suppressing generation of Tfh 
cells. The authors suggest that both mediators regulate differ-
entiation of T and B cells in nasal polyp tissue. It is concluded 
that IL21 produced by Tfh cells stimulates GC formation in 
CRSwNP (unpublished data). The group of Mechtcheriakova53 
used CRSwNP as a model to study AID-associated responses in 
diseases characterized by chronic inflammation. In nasal polyp 
tissue, they detected functional AID-positive ectopic follicular 
structures by real-time PCR analysis and immunostaining. No 
AID mRNA could be detected in the control CRSsNP tissue. 
The transcription of IgE and/or IgG was positively correlated 
with the expression of AID mRNA. These results indicate that 
CSR and SHM can take place locally in the airways at sites of 
chronic inflammation. 
SA-Specific IgE 
Local IgE in CRSwNP is polyclonal and associated with the pres-
ence of IgE antibodies to SEs.28,47 SA is one of the most frequently 
found bacteria in CRSwNP. Colonization with SA is significantly 
more prevalent in the population with nasal polyps compared to 
controls. Colonization is present in 27.3% of CRSsNP patients, 
33% of control subjects, 60% of patients with CRSwNP and as 
high as 87% in the subgroup with asthma and aspirin intoler-
ance, based on culture data.54 An increased colonization rate of 
SA was demonstrated in patients with CRSwNP (63.6%), but 
not in those with CRSsNP (27.3%) and control subjects (33%).55 
Immune response rates to enterotoxines released by SA fol-
low the same trend, with SE-specific IgE present in 28% of 
CRSwNP and up to 80% in the subgroup with aspirin-exacer-
bated respiratory disease.55 SE contributes to nasal polyp for-
mation in both atopic and non-atopic patients,46,56 since these 
enterotoxins have the ability to induce enormous activation of 
lymphocytes without undergoing processing by APCs. Conse-
quently, severe eosinophilic inflammation arises, and poly-
clonal IgE and IgG/IgG4 are produced by B cells.51 Products of 
viral or bacterial microorganisms with this feature are identified 
as superantigens. 
The activation of T- and B-cells by T-and B-cell superantigens, 
respectively, is nonspecific and polyclonal, and leads to mas-
sive cytokine release. This resultant polyclonal IgE saturates the 
receptors on local tissue mast cells, reducing the effect of spe-
cific IgE and the allergic response. Superantigens skew the in-
flammation toward Th2-mediated inflammation with in-
creased levels of ECP, IL5, and IgE, or a pre-existing Th2 milieu 
might facilitate the persistence of SA. Moreover, macrophages 
are alternatively activated, causing deficient phagocytosis of SA 
in CRSwNP.57 Detection of IgE specific to SE has been demon-
strated for tissue homogenates, but rarely in serum of subjects 
without comorbid asthma. Moreover, the levels of IgE specific 
to SEA and SEB detected in tissue homogenates correlate with 
levels of ECP and IL5, and thus eosinophilic inflammation.58 
IgE  
Eosinophilic inflammation with elevated IgE found in nasal 
polyps suggests an atopic background, although atopy has no 
impact on tissue inflammatory patterns in Caucasian polyps. 
Epidemiological data support this notion, as CRSwNP is as 
prevalent in atopic patients as in non-atopic patients. Suh et 
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al.59 compared total IgE and HDM-specific IgE in nasal polyp 
tissue from patients with strong or weak systemic hypersensi-
tivity, and controls. They found a high IgE-level in both atopic 
groups, suggesting local IgE production definitely in patients 
with weak systemic atopy. In 2010, Sheahan et al.60 found local 
antigen-specific IgE in 57% of non-atopic nasal polyp tissue, 
supporting the presence of local IgE to both seasonal and pe-
rennial allergens. 
Comorbid asthma 
CRSwNP is often associated with asthma and/or aspirin intol-
erance. CRSwNP and asthma share certain characteristics and 
often coexist, leading to the assumption that they could both be 
an expression of the same Th2-mediated disease. Importantly, 
there is evidence for local IgE synthesis in the bronchial muco-
sa of atopic and non-atopic asthmatics.29 The overexpression of 
IgE and IL5 in nasal polyps of the Th2 subtype of CRSwNP is, 
next to the presence of SE-specific IgE, associated with an in-
creased risk of asthma.42 In patients with nasal polyps and asth-
ma, local IgE is highly elevated as compared to controls, CRSs-
NP, and CRSwNP without asthma (Fig. 2). Sensitization to SE is 
frequent, with  prevalence of positive serum SE-specific IgE of 
29.3% in the European general population and 27% in the Kore-
an adult population.61 Sensitization is more common in smok-
ers, males, and persons sensitized to aeroallergens and of ad-
vanced age.61 Furthermore, serum SE-specific IgE is associated 
with adult-onset asthma61 and could be used as a biomarker. 
Clinical implication: diagnostics 
Diagnostics are insufficient if solely based on clinical and ra-
diographic evaluation of the paranasal sinuses. Differentiation 
between Th2-biased CRSwNP with high local IgE and that 
which is not Th2-biased is relevant in clinical practice and of 
prognostic value, as especially the eosinophilic type is hard to 
treat and has the reputation to relapse. Moreover, Th2-skewed 
inflammation involves an increased level of IL5, and it has been 
demonstrated that this cytokine is related to the development 
of asthma.42 Determining the presence of local SE-specific IgE 
is also important prognostically, as it would be linked to the de-
velopment of asthma as well. Measuring markers like IgE in 
mucosal tissue is the most direct investigation of inflammation 
in the nose. In practice, however, collection of tissue is only rea-
sonable when the patient needs to undergo surgery, as sinus 
mucosa biopsy is an invasive method. 
Assuming that protein levels in nasal secretions correlate with 
those in the underlying tissue, an alternative is to measure local 
markers in nasal secretions. Several techniques are described 
to collect secretions that are all less invasive than biopsy. Nasal 
lavage and absorption techniques by placing filter papers (cel-
lulose sheets) or foam in the nasal cavity are good options. The 
foam or filter paper equilibrates with the ambient fluid and is 
then squeezed by centrifugation. 
At last, analogue to diagnostic techniques in AR, nasal provo-
cation could be a diagnostic tool in CRSwNP. However, con-
verse to AR, a study conducted by Calus et al.62 made it clear 
that this technique has little diagnostic value in CRSwNP. 
Clinical implication: treatment 
Currently, the treatment of CRSwNP consists of medical treat-
ment, but in most cases additional treatment by endoscopic si-
nus surgery is necessary. However, CRSwNP is a chronic dis-
ease with high relapse rates in certain endotypes. New treat-
ment options are emerging to better control the disease, name-
ly antibody treatments. However, given the cost it is likely that 
these tailored treatments will be reserved for patients with se-
vere airway disease refractory to conventional treatment. 
Current medical treatment 
Medical treatment of CRSwNP often requires a combination 
of saline irrigation, topical nasal steroids/oral steroids, and an-
tibiotics. Glucocorticosteroids are potent anti-inflammatory 
drugs that are commonly prescribed in CRSwNP. Topical corti-
costeroid therapy is the first- line treatment of chronic rhinosi-
nusitis and has an effect on polyp size, nasal symptoms, and re-
currence rate. Van Zele et al.63 evaluated the effect of oral gluco-
corticosteroids in a randomized controlled trial and showed a 
significant but short-term effect on polyp size and nasal symp-
toms. In view of the quick recurrence of polyps, they stated that 
treatment with oral steroids is of limited value unless surgery or 
treatment with intranasal corticosteroids is combined.63 
Antibiotics are a treatment option, as a role for microorgan-
isms is proposed. In particular, macrolides and doxycycline are 
Fig. 2. Local IgE levels in nasal tissue homogenates. In the population with 
CRSwNP and comorbid asthma, local IgE is highly elevated, as compared to 
controls, CRSsNP, and CRSwNP without asthma. 
Co, controls; CS, CRSsNP; NP, CRSwNP; NP+Asth, CRSwNP and asthma.
 Co CS NP NP+Asth
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good choices, because they have an anti-inflammatory action 
next to their antibiotic features.63 Macrolides like erythromycin, 
clarithromycin, and roxithromycin affect neutrophils and eo-
sinophils to reduce tissue damage by chronic bacterial coloni-
zation. The tetracycline antibiotic family has good tissue pene-
tration in airway tissue, has a broad spectrum, and is especially 
effective against SA. The effect of doxycycline was examined by 
Van Zele et al.63 and had a significant, albeit more moderate, ef-
fect compared to that of oral glucocorticosteroids. The effect of 
3-week doxycycline treatment with 100 mg/day was present for 
12 weeks, whereas the effect of tapering methylprednisolone 
treatment over the same period only lasted for 8 weeks. 
New treatment options that target IgE directly or indirectly 
By the end of the last century, biological antibodies were de-
veloped, including anti-IL5, anti-IL4Rα, and anti-IgE. Unlike 
corticoids, these specific treatments are only effective in a se-
lected population. Nevertheless, it might be an opportunity to 
predict responsiveness to a certain targeted treatment based on 
different T-cell patterns and cytokines in serum, in mucosa 
when surgery is mandatory, or in nasal secretions. 
1) Direct inhibition of IgE 
Considering Th2-skewed eosinophilic inflammation with 
marked local production of functional IgE antibodies, it can be 
assumed that treatment with anti-IgE is indicated for this endo-
type. Especially in patients with nasal polyps and comorbid 
asthma, treatment targeting IgE can be advocated, as high local 
IgE is frequently present in this subpopulation (Fig. 2). Indeed, 
this therapy has proven to be successful in CRSwNP and co-
morbid asthma with a substantial decrease in nasal polyp 
scores after 16 weeks in the omalizumab group, as compared to 
baseline.64 Upper and lower airway symptoms significantly im-
prove by application of anti-IgE therapy in both atopic and non-
atopic patients with nasal polyps. The independence of atopic 
status highlights the functionality of the locally produced IgE. 
This result is in contrast to that of a study conducted by Pinto65 
in 2010. In this randomized controlled trial, the effect of omali-
zumab was determined in patients with chronic sinusitis, as 
compared to placebo. An improvement of sinus opacification 
in CT scans and the SNOT-20 questionnaire was found, but the 
difference was not significant.65 However, the population also 
included patients with CRSsNP, which may partially explain the 
limited benefit from omalizumab; furthermore, the patients 
were using intranasal corticosteroids, which were not tried to 
reduce. From both studies, we can conclude that patients have 
to be selected carefully when considering a treatment or a study 
with a targeted treatment. 
2) Indirect inhibition IgE: Anti-IL4rα, Anti-TSLP, and Anti-IL33 
IL4 is, next to IL13, an important component in airway in-
flammation, as the IL4/IL13/STAT6 pathway is crucial in Th2-
mediated inflammation. Several IL4-antagonizing approaches 
have been proposed, including the soluble recombinant hu-
man IL4 receptor, IL4 mutein, humanized anti-IL4 monoclonal 
antibody, and human anti-IL4 receptor α monoclonal anti-
body. By targeting the α subunit of the IL4 receptor, both IL4 
and IL13 are blocked; this could be more effective than target-
ing either one alone.66 Dupilumab is a fully human monoclonal 
antibody targeting the IL4 receptor α subunit. A randomized 
controlled trial has investigated the efficacy and safety of dupil-
umab in patients with persistent, moderate-to-severe asthma 
and a blood eosinophil count of at least 300 cells per microliter 
or a sputum eosinophil level of at least 3%.67 In view of the good 
clinical result in asthma, it would be interesting to investigate 
the efficacy in eosinophilic CRSwNP. 
As mentioned before, TSLP is an epithelially derived cytokine 
that is important in promoting Th2-type inflammation. An in-
creased expression of messenger RNA for TSLP and an in-
creased number of TSLP-positive cells are demonstrated in na-
sal polyps. Moreover, there is a clear correlation between the 
number of TSLP-positive cells and the IgE level.68 It would be 
interesting to assess the effect of TSLP inhibition on the IgE lev-
el in CRSwNP. AMG 157 is a human antibody targeting TSLP,69 
and thus theoretically this antibody could prevent need to same 
in wole text IgE formation upstream. Similarly, next to TSLP, 
IL33, and IL25 represent a link between the epithelium and the 
Th2-dominated adaptive immunity in CRSwNP (Fig. 1). The 
IL33/ST2 pathway be a therapeutic target, and blockade by 
means of anti-IL33 or soluble ST2 could reduce inflammation 
in nasal polyps. To our knowledge, however, the impact of such 
blockade on local IgE in CRSwNP has not yet been investigated. 
CONCLUSIONS
In many sinonasal diseases, IgE is crucial in the pathogenesis. 
Systemic markers to investigate inflammation in upper airway 
disease are sometimes not representative for local inflamma-
tion. IgE that is locally produced in the target organ could have 
diagnostic and therapeutic importance in AR and CRSwNP. 
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